Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BD set to add HandyLab to molecular Dx offering

This article was originally published in Clinica

Executive Summary

BD is to grow its portfolio of molecular diagnostics technology by purchasing HandyLab, a specialist in assays and automation platforms. The acquisition will follow on from an exclusive partnership between the two firms whereby BD Diagnostics aims to commercialise its molecular assays on a new platform that will integrate benchtop technology developed by Ann Arbor, Michigan-based HandyLab (www.clinica.co.uk, May 19 2009). BD said that it plans to run its GeneOhm molecular assays for methicillin-resisant Staphylococcus aureus (MRSA), Clostridium difficile and vancomycin-resistant Enterococcus (VRE) onto HandyLab’s platform and market them as the BD MAX system. Financial details of the deal, which is expected to close during the first quarter of fiscal 2010, were not disclosed.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT044583

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel